company background image
ADXN

Addex TherapeuticsSWX:ADXN Stock Report

Last Price

CHF0.92

Market Cap

CHF34.9m

7D

-1.1%

1Y

-46.0%

Updated

25 Jan, 2022

Data

Company Financials +
ADXN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ADXN Stock Overview

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.

Price History & Performance

Summary of all time highs, changes and price drops for Addex Therapeutics
Historical stock prices
Current Share PriceCHF0.92
52 Week HighCHF1.98
52 Week LowCHF0.80
Beta1.33
1 Month Change-12.80%
3 Month Change-23.97%
1 Year Change-46.04%
3 Year Change-59.65%
5 Year Change-60.00%
Change since IPO-98.65%

Recent News & Updates

Nov 23
Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?

Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

ADXNCH BiotechsCH Market
7D-1.1%-1.2%-4.4%
1Y-46.0%-37.0%8.8%

Return vs Industry: ADXN underperformed the Swiss Biotechs industry which returned -37.7% over the past year.

Return vs Market: ADXN underperformed the Swiss Market which returned 8.9% over the past year.

Price Volatility

Is ADXN's price volatile compared to industry and market?
ADXN volatility
ADXN Average Weekly Movement6.4%
Biotechs Industry Average Movement6.8%
Market Average Movement4.1%
10% most volatile stocks in CH Market7.2%
10% least volatile stocks in CH Market2.0%

Stable Share Price: ADXN is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ADXN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Swiss stocks.

About the Company

FoundedEmployeesCEOWebsite
200227Tim Dyerhttps://www.addextherapeutics.com

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction.

Addex Therapeutics Fundamentals Summary

How do Addex Therapeutics's earnings and revenue compare to its market cap?
ADXN fundamental statistics
Market CapCHF34.87m
Earnings (TTM)-CHF13.05m
Revenue (TTM)CHF4.64m

7.5x

P/S Ratio

-2.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ADXN income statement (TTM)
RevenueCHF4.64m
Cost of RevenueCHF11.84m
Gross Profit-CHF7.20m
ExpensesCHF5.86m
Earnings-CHF13.05m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Mar 07, 2022

Earnings per share (EPS)-0.34
Gross Margin-154.98%
Net Profit Margin-281.08%
Debt/Equity Ratio0%

How did ADXN perform over the long term?

See historical performance and comparison

Valuation

Is Addex Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ADXN (CHF0.92) is trading below our estimate of fair value (CHF4.47)

Significantly Below Fair Value: ADXN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ADXN is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: ADXN is unprofitable, so we can't compare its PE Ratio to the Swiss market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ADXN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ADXN's PB Ratio (2.6x) is in line with the CH Biotechs industry average.


Future Growth

How is Addex Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

42.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ADXN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.3%).

Earnings vs Market: ADXN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ADXN's is expected to become profitable in the next 3 years.

Revenue vs Market: ADXN's revenue (35.8% per year) is forecast to grow faster than the Swiss market (4.8% per year).

High Growth Revenue: ADXN's revenue (35.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ADXN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Addex Therapeutics performed over the past 5 years?

-38.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ADXN is currently unprofitable.

Growing Profit Margin: ADXN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ADXN is unprofitable, and losses have increased over the past 5 years at a rate of 38.7% per year.

Accelerating Growth: Unable to compare ADXN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ADXN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (50.7%).


Return on Equity

High ROE: ADXN has a negative Return on Equity (-97.84%), as it is currently unprofitable.


Financial Health

How is Addex Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ADXN's short term assets (CHF17.4M) exceed its short term liabilities (CHF3.3M).

Long Term Liabilities: ADXN's short term assets (CHF17.4M) exceed its long term liabilities (CHF1.4M).


Debt to Equity History and Analysis

Debt Level: ADXN is debt free.

Reducing Debt: ADXN had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ADXN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ADXN is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.


Dividend

What is Addex Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ADXN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ADXN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ADXN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ADXN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ADXN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.2yrs

Average management tenure


CEO

Tim Dyer (53 yo)

20yrs

Tenure

Mr. Timothy Mark Dyer, also known as Tim, has been Chief Executive Officer at Addex Therapeutics Ltd. since June 1, 2013. Mr. Dyer co-founded Addex Therapeutics Ltd.(also known as Addex Pharmaceuticals Lt...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD997.89K) is above average for companies of similar size in the Swiss market ($USD561.45K).

Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ADXN's management team is seasoned and experienced (5.2 years average tenure).


Board Members

Experienced Board: ADXN's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.6%.


Top Shareholders

Company Information

Addex Therapeutics Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: Addex Therapeutics Ltd
  • Ticker: ADXN
  • Exchange: SWX
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CHF34.868m
  • Shares outstanding: 37.90m
  • Website: https://www.addextherapeutics.com

Number of Employees


Location

  • Addex Therapeutics Ltd
  • Chemin des Mines, 9
  • Geneva
  • Geneva
  • 1202
  • Switzerland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/25 21:37
End of Day Share Price2022/01/25 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.